A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

被引:0
作者
Perez, EA
Hillman, DW
Stella, PJ
Krook, JE
Hartmann, LC
Fitch, TR
Hatfield, AK
Mailliard, JA
Nair, S
Kardinal, CG
Ingle, JN
机构
[1] Mayo Clin & Mayo Fdn, Div Hematol Oncol, Rochester, MN 55905 USA
[2] Ann Arbor Reg CCOP, Ann Arbor, MI USA
[3] Duluth CCOP, Duluth, MN USA
[4] Scottsdale CCOP, Scottsdale, AZ USA
[5] Carle Canc Ctr CCOP, Urbana, IL USA
[6] Missouri Valley Consortium, Omaha, NE USA
[7] Geisinger Clin & Med Ctr CCOP, Dept Hematol & Oncol, Danville, PA USA
[8] Ochsner CCOP, New Orleans, LA USA
关键词
paclitaxel; carboplatin; breast carcinoma; first-line chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m(2) by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. METHODS. Eligible patients had measurable metastatic disease and an Eastern Cooperative Oncology Group performance status of 0-2. Prior adjuvant chemotherapy, including anthracycline-based therapy, was allowed, as was prior hormonal therapy as part of either adjuvant treatment or treatment for metastasis. Prior therapy with taxanes or platinum was not allowed. RESULTS, A total of 53 patients were enrolled in this study, with 50 patients evaluable for response and toxicity. The overall response rate was 62% (95% confidence interval [CI], 48-75%); 16% of patients had complete responses and 46% had partial responses. The median time to progression was 7.3 months (95% CI, 5.9-12.9), and the 12-month survival estimate was 72% (95% CI, 61-86%). Therapy was generally well tolerated. Grade 3-4 neutropenia was the predominant toxicity, observed in 82% of patients, but there were no episodes of febrile neutropenia or sepsis. Hematopoietic growth factors were not routinely necessary. Grade 3 peripheral neuropathy occurred in 16% of patients. CONCLUSIONS. Paclitaxel (200 mg/m(2)) with carboplatin (area under the curve 6 mg/mL per minute) demonstrated substantial efficacy in patients with metastatic breast carcinoma, and the 12-month survival rate of 72% was encouraging. This therapy represents a viable option for patients with metastatic disease. Cancer 2000;88:124-31. (C) 2000 American Cancer Society.
引用
收藏
页码:124 / 131
页数:8
相关论文
共 50 条
[41]   A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer [J].
Mori, Kiyoshi ;
Kobayashi, Hiroyuki ;
Kamiyama, Yukari ;
Kano, Yasuhiko ;
Kodama, Tetsuro .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) :73-78
[42]   Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer [J].
Park, Yeon Hee ;
Im, Seock-Ah ;
Kim, Sung-Bae ;
Sohn, Joo Hyuk ;
Lee, Keun Seok ;
Chae, Yee Soo ;
Lee, Ki Hyeong ;
Kim, Jee Hyun ;
Im, Young-Hyuck ;
Kim, Ji-Yeon ;
Kim, Tae-Yong ;
Lee, Kyung-Hun ;
Ahn, Jin-Hee ;
Kim, Gun Min ;
Park, In Hae ;
Lee, Soo Jung ;
Han, Hye Sook ;
Kim, Se Hyun ;
Jung, Kyung Hae .
EUROPEAN JOURNAL OF CANCER, 2017, 86 :385-393
[43]   First-Line Chemotherapy for Metastatic Breast Cancer [J].
Telli, Melinda L. ;
Carlson, Robert W. .
CLINICAL BREAST CANCER, 2009, 9 :S66-S72
[44]   Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy [J].
Eltabbakh, GH ;
Yildirim, Z ;
Adamowicz, R .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01) :46-50
[45]   Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer [J].
Lueck, Hans-Joachim ;
Luebbe, Kristina ;
Reinisch, Mattea ;
Maass, Nicolai ;
Feisel-Schwickardi, Gabriele ;
Tome, Oliver ;
Janni, Wolfgang ;
Aydogdu, Mustafa ;
Neunhoeffer, Tanja ;
Ober, Angelika ;
Aktas, Bahriye ;
Park-Simon, Tjoung-Won ;
Schumacher, Claudia ;
Hoeffkes, Heinz-Gert ;
Illmer, Thomas ;
Wagner, Harald ;
Mehta, Keyur ;
von Minckwitz, Gunter ;
Nekljudova, Valentina ;
Loibl, Sibylle .
BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) :141-149
[47]   Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial [J].
Binghe Xu ;
Zefei Jiang ;
Sung-Bae Kim ;
Shiying Yu ;
Jifeng Feng ;
Artur Malzyner ;
Auro del Giglio ;
Hyun C. Chung ;
Li Jun Shen ;
Daniel Lee Kay Pen .
Breast Cancer, 2011, 18 :203-212
[48]   Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy [J].
Nisman, B ;
Barak, V ;
Hubert, A ;
Kaduri, L ;
Lyass, O ;
Baras, M ;
Peretz, T .
ANTICANCER RESEARCH, 2003, 23 (2C) :1939-1942
[49]   Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial [J].
Zhou, T. ;
Yang, Y. ;
Ma, S. ;
Lin, L. ;
Zhou, T. ;
Zhang, C. ;
Ding, X. ;
Wang, R. ;
Feng, G. ;
Chen, Y. ;
Xu, R. ;
Huang, Y. ;
Zhang, L. .
ESMO OPEN, 2021, 6 (06)
[50]   A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer [J].
Kang, H. J. ;
Chang, H. M. ;
Kim, T. W. ;
Ryu, M-H ;
Sohn, H-J ;
Yook, J. H. ;
Oh, S. T. ;
Kim, B. S. ;
Lee, J-S ;
Kang, Y-K .
BRITISH JOURNAL OF CANCER, 2008, 98 (02) :316-322